PF 3845
| 中文名称 | PF 3845 |
|---|---|
| 中文同义词 | PF-3845 N-3-吡啶-4-[[3-[[5-(三氟甲基)-2-吡啶]氧基]苯基]甲基]-1-哌啶羧酰胺;N-3-吡啶基-4-[[3-[[5-(三氟甲基)-2-吡啶基]氧基]苯基]甲基]-1-哌啶甲酰胺;N-3-吡啶-4-[[3-[[5-(三氟甲基)-2-吡啶]氧基]苯基]甲基]-1-哌啶羧酰胺;化合物PF-3845;N-(吡啶-3-基)-4-(3-((5-(三氟甲基)吡啶-2-基)氧基)苄基)哌啶-1-酰胺;PF-3845,不可逆FAAH抑制剂;PF-3845,FAAH抑制剂;化合物PF-3845,10 MM DMSO 溶液 |
| 英文名称 | PF 3845 |
| 英文同义词 | PF3845/PF-3845;N-3-Pyridinyl-4-[[3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]methyl]-1-piperidinecarboxamide;PF 3845;4-(3-(5-(trifluoromethyl)pyridin-2-yloxy)benzyl)-N-(pyridin-3-yl)piperidine-1-carboxamide;N-3-Pyridinyl-4-[[3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]methyl]-1-piperidinecarboxamide PF 3845;N-3-Pyridinyl-4-[[3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]methyl]-1-piperidinecarboxamide hydrate;PF 3845 hydrate;N-3-Pyridinyl-4-[[3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]methyl]-1-piperidinecarboxami |
| CAS号 | 1196109-52-0 |
| 分子式 | C24H23F3N4O2 |
| 分子量 | 456.46 |
| EINECS号 | |
| 相关类别 | 代谢;小分子抑制剂，天然产物;信号转导通路激酶抑制剂;Inhibitors;Inhibitor;Pharmaceutical intermediate |
| Mol文件 | 1196109-52-0.mol |
| 结构式 |  |
PF 3845 性质
| 沸点 | 623.6±55.0 °C(Predicted) |
|---|---|
| 密度 | 1.323±0.06 g/cm3(Predicted) |
| 储存条件 | 2-8°C |
| 溶解度 | 在DMSO中的溶解度≥45mg/mL |
| 酸度系数(pKa) | 14.14±0.40(Predicted) |
| 形态 | 粉末 |
| 颜色 | 白色至棕褐色 |
| InChIKey | CVQMBUCCSAKASE-UHFFFAOYSA-N |
| SMILES | O.FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc4cccnc4)c2)nc1 |
Ki: 0.23 µM (FAAH)
PF-3845 (0.5 nM-10 μM; 40 min) inhibits human FAAH-1 (IC
50
=18 nM) in a concentration-dependent manner, and shows negligible activity against FAAH-2 (IC
50
>10 μM) in COS-7 cells.
PF-3845 (0.1-1000 μM; 48 h) significantly decreases the Colo-205 cell viability.
PF-3845 (1-30 mg/kg; p.o.) produces cannabinoid receptor-dependent reductions in inflammatory pain in rat.
PF-3845 (10 mg/kg; a single i.p.) selectively inhibits FAAH in mice for up to 24 hours.
PF-3845 (10 mg/kg; a single i.p.) causes a dramatic and sustained elevation in Anandamide (AEA) in mice.
| Animal Model: | Male Sprague-Dawley rats (200g- 250g) are injected CFA |
| Dosage: | 1, 3, 10, 30 mg/kg |
| Administration: | Oral administration |
| Result: | Caused a dose-dependent inhibition of mechanical allodynia with a minimum effective dose (MED) of 3 mg/kg. |
PF 3845 is a selective fatty acid amide hydrolase (FAAH) inhibitor (Ki = 0.23 μM). Reduces inflammatory pain via a cannabinoid receptor-dependent mechanism. Highly efficacious and selective in vivo. D isplays no activity at FAAH-2 (IC50 >10 μM).
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2025/12/22 | HY-14380 | PF-3845 | 1196109-52-0 | 1 mg | 278元 |
| 2025/12/22 | HY-14380 | PF 3845 PF-3845 | 1196109-52-0 | 5mg | 512元 |